The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in 2025 ...
Cathie Wood says a "cure" can generate up to 20x more value than traditional drugs, which appears to explain why two of her firm's funds snapped up shares of the Casgevy co-developer until this past ...